The primary objective of the study is to assess the safety of CC-1088 to patients with
myelodysplastic syndromes (MDS).
- Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not
- Patient must be able to adhere to the study visit schedule and other protocol
- Patient must understand and voluntarily sign an informed consent document.
- Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
- Women must not be pregnant or lactating.